Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Director | December 07, 2012 | December 07, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date December 07, 2012 · Filed December 07, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2012-12-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2013 · Filed March 02, 2013
Section 16 reporting ended · disclosed 2013-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 137,475 |
Reported balance
After 2013-02-28 transaction · row 1
1 source rowRow 1 · 2013-02-28 · Tax withholding · Disposed 9,188 · Balance 137,475 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 4,134 |
Reported balance
Holding disclosure · report date 2013-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,134 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2013.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2013 Filed Mar 2, 2013 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,188 | $34.26 | $314,780.88 |
DisclosureSEC source: 0001179110-13-003895 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,475 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,314 | $34.76 | $45,678.58 |
DisclosureSEC source: 0001179110-13-003142 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,663 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,912 | $35.08 | $102,152.96 |
DisclosureSEC source: 0001179110-13-003142 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,977 Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 106,600 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003142 · edgar.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,600 Underlying: Common shares · 106,600 shares Expires 2023-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,534 on 2/15/2014, 35,533 on 2/15/2015, and 35,533 on 2/15/2016. Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003142 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,889 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 14, 2012 Filed Sep 17, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,613 | $0.00 Strike: $69.27 | $0.00 |
DisclosureSEC source: 0001179110-12-014149 · edgar.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,613 Underlying: Common shares · 1,613 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 14, 2012 Filed Sep 17, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,839 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001179110-12-014149 · edgar.xml · derivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,839 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 14, 2012 Filed Sep 17, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,613 | $69.27 | $111,732.51 |
DisclosureSEC source: 0001179110-12-014149 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,289 Read SEC document |
| September 14, 2012 Filed Sep 17, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,839 | $54.74 | $100,666.86 |
DisclosureSEC source: 0001179110-12-014149 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 18,043 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001179110-12-012179 · edgar.xml · derivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,043 Underlying: Common shares · 18,043 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,565 | $0.00 Strike: $52.49 | $0.00 |
DisclosureSEC source: 0001179110-12-012179 · edgar.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,565 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,991 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001179110-12-012179 · edgar.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 14,991 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 18,043 | $66.39 | $1,197,874.77 |
DisclosureSEC source: 0001179110-12-012179 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,063 Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,565 | $52.49 | $292,106.85 |
DisclosureSEC source: 0001179110-12-012179 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,991 | $52.55 | $787,777.05 |
DisclosureSEC source: 0001179110-12-012179 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2012 Filed Mar 29, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 29,331 | $61.35 | $1,799,456.85 |
DisclosureSEC source: 0001179110-12-005942 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,550 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,851 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · derivative · entry 27 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,851 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,548 | $0.00 Strike: $58.71 | $0.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · derivative · entry 26 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 13,548 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,630 | $0.00 Strike: $56.30 | $0.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · derivative · entry 25 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,630 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,677 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · derivative · entry 24 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 12,677 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $60.14 | $36,085.50 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 22 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,881 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $60.14 | $66,154.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 21 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,481 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $60.14 | $60,135.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 20 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,581 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $60.13 | $120,260.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 19 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,581 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $60.13 | $18,037.50 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 18 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,581 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,572 | $60.12 | $154,628.64 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 17 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,881 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $60.12 | $24,046.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 16 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,453 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,584 | $60.11 | $215,434.24 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 15 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,853 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $60.11 | $6,010.50 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 14 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,437 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 18,942 | $60.10 | $1,138,414.20 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 13 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,537 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $60.09 | $120,180.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 12 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,479 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $60.09 | $18,025.50 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 11 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,479 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,308 | $60.08 | $78,584.64 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 10 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,779 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $60.08 | $12,015.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 9 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,087 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $60.07 | $138,161.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,287 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $60.07 | $24,026.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,587 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $60.06 | $60,060.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,987 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $60.06 | $36,033.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,987 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,851 | $54.74 | $101,323.74 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,548 | $58.71 | $795,403.08 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,630 | $56.30 | $598,469.00 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,677 | $52.55 | $666,176.35 |
DisclosureSEC source: 0001179110-12-005695 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $56.70 | $45,362.40 |
DisclosureSEC source: 0001179110-12-004082 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,881 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 488 | $56.70 | $27,670.58 |
DisclosureSEC source: 0001179110-12-004082 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,681 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,408 | $57.04 | $422,552.32 |
DisclosureSEC source: 0001179110-12-004082 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,169 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 34,400 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003239 · edgar.xml · derivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Underlying: Common shares · 34,400 shares Expires 2022-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,467 on 02/17/2013, 11,466 on 02/17/2014, and 11,467 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003239 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,577 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 22, 2011 Filed Dec 23, 2011 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 32,642 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-017126 · edgar.xml · derivative · entry 23 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 32,642 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 22, 2011 Filed Dec 23, 2011 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 42,561 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-017126 · edgar.xml · derivative · entry 22 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 42,561 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 22, 2011 Filed Dec 23, 2011 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $55.34 | $5,533.50 |
DisclosureSEC source: 0001179110-11-017126 · edgar.xml · nonDerivative · entry 20 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,577 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.